- Home
- PGEN
PGEN
Precigen Inc.
as of 11-28-2025 12:39pm EST
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | GERMANTOWN |
| Market Cap: | 1.5B | IPO Year: | N/A |
| Target Price: | $7.67 | AVG Volume (30 days): | 4.8M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.65 - $5.22 | Next Earning Date: | 11-13-2025 |
| Revenue: | $6,309,000 | Revenue Growth: | 59.20% |
| Revenue Growth (this year): | 249.1% | Revenue Growth (next year): | 710.03% |
AI-Powered PGEN Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Precigen Inc. (PGEN)
Director, 10% Owner
Avg Cost/Share
$3.41
Shares
1,809,667
Total Value
$6,170,964.47
Owned After
14,597,161
SEC Form 4
Director
Avg Cost/Share
$3.38
Shares
106,837
Total Value
$361,109.06
Owned After
346,070
SEC Form 4
Chief Commercial Officer
Avg Cost/Share
$3.58
Shares
6,000
Total Value
$21,480.00
Owned After
65,031
SEC Form 4
Director
Avg Cost/Share
$3.60
Shares
67,523
Total Value
$243,082.80
Owned After
346,070
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$3.42
Shares
2,932
Total Value
$10,027.44
Owned After
468,626
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$3.40
Shares
2,000
Total Value
$6,800.00
Owned After
405,959
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$3.62
Shares
8,284
Total Value
$29,988.08
Owned After
468,626
SEC Form 4
Director
Avg Cost/Share
$4.60
Shares
15,000
Total Value
$69,000.00
Owned After
217,841
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| KIRK RANDAL J | PGEN | Director, 10% Owner | Sep 30, 2025 | Sell | $3.41 | 1,809,667 | $6,170,964.47 | 14,597,161 | |
| KINDLER JEFFREY B | PGEN | Director | Sep 30, 2025 | Sell | $3.38 | 106,837 | $361,109.06 | 346,070 | |
| Tennant Phil | PGEN | Chief Commercial Officer | Sep 29, 2025 | Buy | $3.58 | 6,000 | $21,480.00 | 65,031 | |
| KINDLER JEFFREY B | PGEN | Director | Sep 29, 2025 | Sell | $3.60 | 67,523 | $243,082.80 | 346,070 | |
| Thomasian Harry Jr. | PGEN | Chief Financial Officer | Sep 26, 2025 | Buy | $3.42 | 2,932 | $10,027.44 | 468,626 | |
| Shah Rutul R | PGEN | Chief Operating Officer | Sep 26, 2025 | Buy | $3.40 | 2,000 | $6,800.00 | 405,959 | |
| Thomasian Harry Jr. | PGEN | Chief Financial Officer | Sep 25, 2025 | Buy | $3.62 | 8,284 | $29,988.08 | 468,626 | |
| AGEE NANCY H | PGEN | Director | Sep 4, 2025 | Buy | $4.60 | 15,000 | $69,000.00 | 217,841 |
Compare PGEN vs Leading Stocks
See how PGEN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PGEN Precigen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.